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iming the Implantation
f Implantable Cardioverter-
efibrillators in Patients With
onischemic Cardiomyopathy*
rancis E. Marchlinski, MD, FACC,
ariell Jessup, MD, FAHA
hiladelphia, Pennsylvania
he prophylactic use of implantable cardioverter-
efibrillators (ICDs) in selected patients with nonischemic
ardiomyopathy (NICM) is unequivocally valuable (1).
linicians are nevertheless confronted with decision making
elated to two fundamental aspects in the selection of
atients for an ICD. First is the use of a single and poorly
eproducible dichotomous variable, left ventricular ejection
raction (LVEF) above or below 35%, as the sole means by
hich to stratify risk. Second is the difficulty in distinguish-
ng patients with a cardiomyopathy, who might benefit from
arly device implantation, from those in whom a marked
mprovement of left ventricular function averts the need for
n ICD.
See page 2477
The arbitrary selection of LVEF 35% as the major
nclusion criterion in the Sudden Cardiac Death-Heart Failure
rial (SCD-HeFT) and Defibrillators in Non-Ischemic Car-
iomyopathy Treatment Evaluation (DEFINITE) trial de-
igns is confounded by the variability of LVEF measurement
ven during stable clinical conditions (1,2). There are no
upplementary criteria in these patients to further stratify
isk for lethal tachyarrhythmia if their LVEF value is
mbiguous. Unfortunately, the scope of those trials makes it
mprobable that repeat studies with different inclusion
arameters will be undertaken. A well-designed registry of
atients with NICM, an LVEF 35%, and a prophylactic
CD could result in data collection that identifies supple-
entary parameters associated with a high arrhythmia risk.
hese parameters, applied prospectively, may prove suffi-
iently robust to narrow the scope of ICD use in patients
ith LVEF 35% and incorporate a larger denominator of
atients with LVEF 35%.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Medicine, University of Pennsylvania School
f Medicine, Philadelphia, Pennsylvania. Dr. Marchlinski has participated in spon-
ored research protocols funded by Guidant, Medtronic, and St. Jude Medical and hasd
ectured at fellows training programs sponsored by Guidant, Medtronic, and St. Jude
edical.In this issue of the Journal, Kadish et al. (3) address the
econd difficult decision—the timing of ICD implantation.
his post hoc analysis of the DEFINITE trial was un-
oubtedly provoked by the Center for Medicare and Med-
caid Services’ decision to restrict prophylactic ICD implan-
ation in patients with NICM for nine months after initial
iagnosis (4). This restriction is absolute for patients within
hree months of the diagnosis, and permitted only as part of
registry for patients diagnosed within three to nine
onths. It is noteworthy that in both the SCD-HeFT and
EFINITE trials, inclusion criteria did not specify a time
imit for study entry but required the exclusion of patients
ith a reversible cardiomyopathy (1,2). Despite the limits of
post hoc analysis, the current report documents the benefit
f ICD implantation in patients with a more recent diag-
osis of NICM in the DEFINITE study population. These
esults are provocative and focus the clinical imperative to
dentify the likelihood of reversibility of the cardiomyopa-
hy. Parameters that define the likelihood of reversibility, as
pposed to a biologically implausible time interval after
iagnosis, should dictate ICD implantation.
It seems that the DEFINITE investigators identified
ersistent arrhythmia risk because the two treatment arms
ontinued to diverge in the early diagnosis group. However,
he report does not substantiate whether they identified the
rreversibility of the cardiomyopathy with their exclusion/
nclusion criteria. Follow-up LVEF information in the
EFINITE population should be ascertained so that the
elationship of improvement in LVEF to the time of entry
n the study could be explored. Better-defined, objective
arameters to identify patients with the possibility of im-
rovement must be confirmed and stipulated.
Reversible cardiomyopathy, such as that produced by a
ersistent tachycardia, or fulminant myocarditis is easily
dentified, but accounts for only a small fraction of the total
atients symptomatic with NICM (5). Our ability to
dentify the reversibility of the cardiomyopathy in other less
bvious settings is more uncertain. New observations related
o the potential for reversible cardiomyopathy caused by
aroxysmal arrhythmias, frequent ventricular ectopy, and
ntermittent right ventricular pacing highlight this difficulty,
uggesting that the arrhythmia burden that adversely affects
VEF may vary from patient to patient and over the clinical
ourse of the disease (6–8). Currently, aggressive manage-
ent to limit the patient’s arrhythmia burden and/or right
entricular pacing with repeat assessment of LVEF is the
ppropriate approach before ICD implantation.
The reversibility of left ventricular dysfunction is also well
ecognized in many patients with NICM in response to
edical treatment with angiotensin-converting enzyme in-
ibitors and beta-blockers (9). Over 50% of patients with
ilated cardiomyopathy may experience substantive (10%)
mprovement in LVEF. This improvement in left ventric-
lar function represents reverse remodeling of a time-
ependent nature. Indeed, the question is not whether the
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Editorial Comment June 20, 2006:2483–5VEF improves in some patients with newly diagnosed
ICM in response to optimized medical therapy, but rather
ow to identify the nonresponder so that an interval of
bservation is not required before ICD implantation.
There are available biologic parameters that have prog-
ostic significance in patients with NICM. Patients with an
ncreased expression of Fas, a transmembrane cell surface
eceptor that plays a critical role in apoptosis, are more likely
o show minimal recovery in LVEF (10). One of the best
iologic markers for irreversibility seems to be related to the
evelopment of significant cardiac fibrosis. Fibrosis serves as
n arrhythmogenic substrate and site of origin for most
ustained ventricular arrhythmias in NICM and reflects the
hronicity of the process (11). Fibrosis in the setting of
onischemic right and left ventricular cardiomyopathy tends
o be predominantly perivalvular. This fibrosis can be
dentified by sinus rhythm and bipolar-voltage catheter
apping, and may also be identified with noninvasive
ontrast-enhanced imaging techniques (11–13). Other in-
irect indices for the presence of perivalvular fibrosis include
ersistent atrioventricular block or proximal left bundle
ranch block. Subsequent observations need to confirm that
atients who show these abnormalities have both a higher
rrhythmia risk and a lower likelihood of improvement in
VEF. Ideally, evidence of significant fibrosis will add
rognostic information to identify patients who warrant
CD therapy despite a recent diagnosis of NICM.
There are also clinical parameters with prognostic signif-
cance in patients with NICM. These clinical factors could
lso be tested prospectively as markers for the severity and
hronicity of the disease process and the likelihood of
rreversibility in left ventricular dysfunction. These factors
nclude the presence of pulmonary hypertension, marked
mpairment in LVEF to 20%, left ventricular end-
iastolic dimension of 7.0 cm, coexistent right ventricular
ysfunction, and an increased degree of left ventricular
phericity (14). Clinical findings such as a persistent S3
allop, signs of right-sided heart failure, hyponatremia,
ncreased B-type natriuretic peptide, and elevated troponin
evels may also be associated with a decreased likelihood of
eversibility (15). Provocative maneuvers, such as dobut-
mine stress testing, have also been used to predict persis-
ent left ventricular dysfunction during follow-up (16).
mportantly, although improvement in left ventricular func-
ion with medical therapy may take more than six months to
ptimize, evidence of some improvement within one to
hree months after initiating therapy is usually observed (9).
he absence of any substantive improvement in LVEF after
wo months of optimum medical therapy also may serve as
marker for the absence of a long-term response.
Finally, there is yet another group of patients with NICM
hat needs to be identified early after diagnosis, i.e., those
atients unable to respond to medical treatment because the
rugs cannot be tolerated (17). Whether such patients
enefit from implantation of an ICD has not been substan-
iated. Thus, the mandate raised by the current report in theournal is not only to identify patients with an irreversible
bnormality not likely to respond to medical intervention,
ut also to identify patients in whom such evidence-based
herapy cannot be used.
In summary, enough doubt is present to question the
isdom of requiring a nine-month observational period in
atients with NICM before the implantation of an ICD.
he clinical imperative is to identify which patients are
ikely to have irreversible LV dysfunction at the time of
nitial presentation. Collecting follow-up data on LVEF
rom patients enrolled in the DEFINITE and SCD-HeFT
rials is an important effort to initiate. The results may
rovide insight into how common left ventricular dysfunc-
ion is reversed when patients are excluded with known
eversible causes of cardiomyopathy. Parameters for defin-
ng a high likelihood of reversible myopathy should be
ncorporated into the guidelines for implantation. Patients
ho show biological, electrophysiological, imaging, or clin-
cal parameters that suggest a high likelihood of irrevers-
bility of left ventricular dysfunction should be considered
or early implantation. This could be done in conjunction
ith a compulsory registry incorporating serial follow-up of
VEF as part of the implantation strategy. An active
trategy that couples evidence-based medicine with sound,
ypothesis-testing, prospective data collection and recog-
izes the importance of distinguishing reversible and non-
eversible forms of NICM should be the norm.
eprint requests and correspondence: Dr. Francis E. Marchlin-
ki, Hospital of the University of Pennsylvania, 3400 Spruce Street,
hiladelphia, Pennsylvania 19104. E-mail: francis.marchlinski@
phs.upenn.edu.
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